A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

Launched by REGENERON PHARMACEUTICALS · Nov 14, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well a medication called DUPIXENT® (dupilumab) works for people with eosinophilic esophagitis (EoE), a condition that affects the esophagus and can make swallowing difficult. The study is observational, meaning researchers will gather information about how patients are treated with DUPIXENT in regular care settings. By understanding the experiences of patients using this medication, the study aims to improve knowledge about EoE and help guide future treatments.

To participate, individuals must be starting DUPIXENT for EoE and able to fill out questionnaires about their symptoms and quality of life. This includes adolescents as well as adults. Participants will be asked how EoE affects their daily lives, how they feel, and whether their symptoms change during the study. The trial is currently recruiting participants, and anyone interested should check if they meet the eligibility criteria before joining.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • 1. Initiating treatment with DUPIXENT® for EoE according to the USPI
• • 2. Able to understand and complete registry-related questionnaires (including adolescents)
• Key Exclusion Criteria:
• • 1. Patients who have a contraindication to DUPIXENT® according to the USPI
• • 2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment
• • 3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator)
• • NOTE: Other protocol defined inclusion/exclusion criteria apply